Surgery and radiotherapy in the treatment of cutaneous melanoma

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Testori, A ^a   Rutkowski, P ^b   Marsden, J ^c   Bastholt, L ^d   Chiarion Sileni, V ^e   Hauschild, A ^f   Eggermont, A M M ^g  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c University Hospitals   (United Kingdom)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f UNIVERSITY OF KIEL   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cutaneous melanoma; Electrochemotherapy; Limb perfusion; Melanoma radiotherapy; Melanoma surgery; Sentinel node

Indexed keywords

HUMAN; MELANOMA; METASTASIS; PATHOLOGY; REVIEW; SKIN TUMOR;

HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 70349575099     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp257     Document Type: Article

References (99)

1. Salopek TG, Slade J, Marghoob AA et al. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. I. Survey of biopsy practices of pigmented lesions suspected as melanoma. J Am Acad Dermatol 1995; 33: 441-450.
2. Argenziano G, Soyer HP, Chimenti S et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48: 679-693.
3. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol 2007; 127: 380-384.
4. Gimotty PA, Elder DE, Fraker DL et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007; 25: 1129-1134.
5. Eggermont AM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 2007; 34: 509-515.
6. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003; 46: 419-426.
7. Lens MB, Dawes M, Goodacre T, Bishop JA. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg 2002; 137: 1101-1105.
8. Khayat D, Rixe O, Martin G et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1 mm thick). Cancer 2003; 97: 1941-1946.
9. Cohn-Cedermark G, Rutqvist LE, Andersson R et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2 cm versus 5 cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89: 1495-1501.
10. Veronesi U, Cascinelli N, Adamus J et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318: 1159-1162.
11. Balch CM, Urist MM, Karakousis CP et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-267.
12. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
13. Thomas JM, Newton-Bishop J, A'Hern R et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-766.
14. Ringborg U, Brahme EM, Drewiecki K. Randomized trial of a resection margin of 2 cm versus 4 cm for cutaneous malignant melanoma with a tumor thickness of more than 2 mm. World Congress on Melanoma, September 6-10, 2005; Vancouver, British Columbia.
15. Heaton KM, Sussman JJ, Gershenwald JE et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 1998; 5: 322-328.
16. Kenady DE, Brown BW, McBride CM. Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. Surgery 1982; 92: 615-618.
17. Holmstrom H. Surgical management of primary melanoma. Semin Surg Oncol 1992; 8: 366-369.
18. Cohen LM, McCall MW, Hodge SJ et al. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs' micrographic surgery aided by rush permanent sections. Cancer 1994; 73: 2964-2970.
19. Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol 1997; 37: 422-429.
20. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol 2007; 56: 828-834.
21. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83: 1664-1678.
22. Gorsky M, Epstein JB. Melanoma arising from the mucosal surfaces of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86: 715-719.
23. Loree TR, Mullins AP, Spellman J et al. Head and neck mucosal melanoma: a 32-year review. Ear Nose Throat J 1999; 78: 372-375.
24. Irvin WP Jr, Legallo RL, Stoler MH et al. Vulvar melanoma: a retrospective analysis and literature review. Gynecol Oncol 2001; 83: 457-465.
25. Rose PG, Piver MS, Tsukada Y, Lau T. Conservative therapy for melanoma of the vulva. Am J Obstet Gynecol 1988; 159: 52-55.
26. Phillips GL, Bundy BN, Okagaki T et al. Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group. Cancer 1994; 73: 2626-2632.
27. Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 1999; 86: 1285-1293.
28. van Geel AN, den Bakker MA, Kirkels W et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology 2007; 70: 143-147.
29. Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum 1995; 38: 146-151.
30. Heaton KM, el-Naggar A, Ensign LG et al. Surgical management and prognostic factors in patients with subungual melanoma. Ann Surg 1994; 219: 197-204.
31. Moehrle M, Metzger S, Schippert W et al. 'Functional' surgery in subungual melanoma. Dermatol Surg 2003; 29: 366-374.
32. Orr DJ, Hughes LE, Horgan K. Management of malignant melanoma of the head and neck. Br J Surg 1993; 80: 998-1000.
33. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146: 1042-1046.
34. Hazan C, Dusza SW, Delgado R et al. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol 2008; 58: 142-148.
35. Veronesi U, Adamus J, Bandiera DC et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297: 627-630.
36. Veronesi U, Adamus J, Bandiera DC et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982; 49: 2420-2430.
37. Cascinelli N, Morabito A, Santinami M et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998; 351: 793-796.
38. Sim FH, Taylor WF, Ivins JC et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer 1978; 41: 948-956.
39. Balch CM, Soong SJ, Bartolucci AA et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255-263.
40. Balch CM, Soong S, Ross MI et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7: 87-97.
41. Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-1317.
42. Morton DL, Thompson JF, Essner R et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230: 453-463.
43. Wong JH, Truelove K, Ko P, Coel MN. Localization and resection of an in transit sentinel lymph node by use of lymphoscintigraphy, intraoperative lymphatic mapping, and a hand-held gamma probe. Surgery 1996; 120: 114-116.
44. Bartolomei M, Testori A, Chinol M et al. Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. Eur J Nucl Med 1998; 25: 1489-1494.
45. Kapteijn BA, Nieweg OE, Liem I et al. Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 1997; 4: 156-160.
46. Testori A, Baldini F, Pelliccia L. Sentinel node biopsy on melanoma patients under local anaesthesia: is it worthwhile? Eur J Cancer 2001; 37 (Suppl 2): 115-116.
47. Cook MG, Green MA, Anderson B et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200: 314-319.
48. van Akkooi AC, de Wilt JH, Verhoef C et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006; 42: 372-380.
49. Cochran AJ, Balda BR, Starz H et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000; 89: 236-241.
50. Starz H. Pathology of the sentinel lymph node in melanoma. Semin Oncol 2004; 31: 357-362.
51. Ruiter DJ, Spatz A, van den Oord JJ, Cook MG. Pathologic staging of melanoma. Semin Oncol 2002; 29: 370-381.
52. van Akkooi AC, de Wilt JH, Verhoef C et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006; 17: 1578-1585.
53. van Akkooi AC, de Wilt JH, Verhoef C, Eggermont AM. Cutaneous melanoma and sentinel lymph node biopsy. Ann Surg Oncol 2008; 15: 1808-1809.
54. Mann GB, Coit DG. Does the extent of operation influence the prognosis in patients with melanoma metastatic to inguinal nodes? Ann Surg Oncol 1999; 6: 263-271.
55. Heenan PJ, Ghaznawie M. The pathogenesis of local recurrence of melanoma at the primary excision site. Br J Plast Surg 1999; 52: 209-213.
56. Koops HS, Vaglini M, Suciu S et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906-2912.
57. Eggermont AM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996; 26: 335-349.
58. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4: 429-437.
59. Lienard D, Ewalenko P, Delmotte JJ et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
60. Grunhagen DJ, Brunstein F, Graveland WJ et al. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004; 240: 939-948.
61. Rossi CR, Foletto M, Mocellin S et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004; 11: 173-177.
62. Grunhagen DJ, van Etten B, Brunstein F et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005; 12: 609-615.
63. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14: 238-247.
64. Mir LM, Belehradek M, Domenge C et al. Electrochemotherapy, a new antitumor treatment: first clinical trial. C R Acad Sci III 1991; 313: 613-618.
65. Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 2000; 10: 585-589.
66. Sarnaik AA, Zager JS, Sondak VK. Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep 2007; 9: 417-427.
67. McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control 2008; 15: 239-247.
68. Doss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys 1982; 8: 1131-1134.
69. Harwood AR, Lawson VG. Radiation therapy for melanomas of the head and neck. Head Neck Surg 1982; 4: 468-474.
70. Vongtama R, Safa A, Gallardo D et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck 2003; 25: 423-428.
71. Arora A, Lowe L, Su L et al. Wide excision without radiation for desmoplastic melanoma. Cancer 2005; 104: 1462-1467.
72. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989; 124: 1051-1055.
73. Ang KK, Peters LJ, Weber RS et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30: 795-798.
74. Rofstad EK. Local tumor control following single dose irradiation of human melanoma xenografts: relationship to cellular radiosensitivity and influence of an immune response by the athymic mouse. Cancer Res 1989; 49: 3163-3167.
75. Rofstad EK. Retention of cellular radiation sensitivity in cell and xenograft lines established from human melanoma surgical specimens. Cancer Res 1992; 52: 1764-1769.
76. Sause WT, Cooper JS, Rush S et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991; 20: 429-432.
77. Stevens G, McKay MJ. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol 2006; 7: 575-583.
78. Kirova YM, Chen J, Rabarijaona LI et al. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 1999; 9: 611-613.
79. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 1988; 15: 859-864.
80. Overgaard J. Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 1980; 6: 41-44.
81. Konefal JB, Emami B, Pilepich MV. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 1987; 164: 607-610.
82. Ballo MT, Ross MI, Cormier JN et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 2006; 64: 106-113.
83. Bonnen MD, Ballo MT, Myers JN et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004; 100: 383-389.
84. Burmeister BH, Smithers BM, Poulsen M et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995; 19: 369-371.
85. Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995; 2: 445-449.
86. Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006; 66: 1051-1055.
87. Creagan ET, Cupps RE, Ivins JC et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer 1978; 42: 2206-2210.
88. Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986; 5: 183-192.
89. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999; 44: 607-618.
90. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol 2002; 29: 518-524.
91. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88: 11-20.
92. Patchell RA. The management of brain metastases. Cancer Treat Rev 2003; 29: 533-540.
93. Ewend MG, Carey LA, Brem H. Treatment of melanoma metastases in the brain. Semin Surg Oncol 1996; 12: 429-435.
94. Tarhini AA, Agarwala SS. Management of brain metastases in patients with melanoma. Curr Opin Oncol 2004; 16: 161-166.
95. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.
96. Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33: 583-590.
97. McWilliams RR, Brown PD, Buckner JC et al. Treatment of brain metastases from melanoma. Mayo Clin Proc 2003; 78: 1529-1536.
98. Grob JJ, Regis J, Laurans R et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur J Cancer 1998; 34: 1187-1192.
99. Brown PD, Brown CA, Pollock BE et al. Stereotactic radiosurgery for patients with 'radioresistant' brain metastases. Neurosurgery 2002; 51: 656-665.